Selecting new upfront regimens for advanced ovarian cancer with biomarker guidance

Journal article

Peer reviewed

John K. Chan, Su-Ying Liang, Daniel S. Kapp, Joshua E. Chan, Thomas J. Herzog, Robert L. Coleman, Bradley J. Monk and Michael T. Richardson

Gynecologic oncology, Vol.159(3), pp.604-606

12/2020

PMID: 32994055

Abstract

Maintenance therapy

Ovarian neoplasms

Poly(ADP-ribose) polymerase inhibitors

5 Record Views

Title: Selecting new upfront regimens for advanced ovarian cancer with biomarker guidance
Creators: John K. Chan - Sutter Health
Su-Ying Liang - Palo Alto Institute
Daniel S. Kapp - Stanford University
Joshua E. Chan - Stanford University School of Medicine
Thomas J. Herzog - University of Cincinnati
Robert L. Coleman - The US Oncology Network
Bradley J. Monk - The US Oncology Network
Michael T. Richardson - Stanford University School of Medicine
Publication Details: Gynecologic oncology, Vol.159(3), pp.604-606
Publisher: Elsevier Inc
Identifiers: 991005969149102656
Academic Unit: Obstetrics & Gynecology
Language: English
Resource Type: Journal article